Update: On November 10, 2021, the Minister rejected Janssen’s second request for data protection for SPRAVATO, which was submitted following the coming into force of the Canada-United States-Mexico Agreement (CUSMA). The...more
On June 9, 2021, the Federal Court of Appeal (FCA), following grant of leave to hear Sunovion’s appeal, dismissed Sunovion’s appeal from a Federal Court (FC) decision of Furlanetto J. (2021 FC 37) granting Taro leave to amend...more
6/17/2021
/ Appeals ,
Canada ,
Dismissals ,
Intellectual Property Protection ,
Leave to Amend ,
Patent Infringement ,
Patent Litigation ,
Patent Validity ,
Patented Medicines ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Section 8
On September 24, 2020, the Supreme Court of Canada denied leave to Apotex (Docket No. 39172) with respect to a decision affirming the quantum of profits payable to the Plaintiffs ADIR and Servier for infringement of ADIR’S...more
11/2/2020
/ Apotex ,
Appeals ,
Canada ,
Health Canada ,
Leave to Appeal ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Profits ,
Supreme Court of Canada
UPDATE: UPDATE: On December 10, 2020, the Supreme Court of Canada dismissed Pfizer’s application for leave to appeal (Docket No. 39150) (see article here).
Pfizer seeks leave in pregabalin section 8 case
As previously...more
6/8/2020
/ Apotex ,
Appeals ,
Canada ,
Dismissals ,
Health Canada ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Janssen Pharmaceuticals ,
Leave to Appeal ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
Section 8 ,
Supreme Court of Canada
UPDATE: On December 10, 2020, the Supreme Court of Canada dismissed Pfizer’s application for leave to appeal (Docket No. 39150)...
As previously reported, Justice O’Reilly of the Federal Court granted Pharmascience’s...more
4/17/2020
/ Appeals ,
Canada ,
Defense Strategies ,
Dismissals ,
Interlocutory Appeals ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Popular ,
Section 8